Tc Biopharm (holdings) PLC

TC Biopharm (Holdings) PLC reports the immediate resignations of directors Mark Bonyhadi and Edward Niemzyck, effective June 26, 2024.

TC Biopharm received a delisting notice from Nasdaq due to non-compliance with minimum stockholders' equity requirements, despite a recent warrant exercise that temporarily restored compliance.

TC Biopharm has regained compliance with Nasdaq's minimum stockholders' equity requirement following a warrant exercise that generated approximately $3.1 million in gross proceeds.

TC BioPharm has entered into an agreement for the immediate exercise of existing warrants, generating approximately $3.1 million in gross proceeds and issuing new warrants for future share purchases.

TC BioPharm has entered into a non-binding letter of intent to acquire a private biotech company focused on innovative CAR-T therapies, marking their second such agreement in recent months.

TC BioPharm has signed a non-binding letter of intent to acquire a cell therapy company's assets, including a solid tumor toolkit, an NK cell manufacturing toolkit, and two CAR-NK programs.

TC BioPharm reported a net loss of $3.3 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.

TC BioPharm (Holdings) PLC has filed an amendment to its 2023 annual report, providing details on executive compensation, share ownership, and related party transactions.

TC BioPharm's annual report reveals ongoing losses and doubts about its ability to continue as a going concern, despite advancements in its gamma delta T-cell therapy programs.

TC BioPharm (Holdings) plc is convening its 2024 Annual General Meeting (AGM) on July 1, 2024, seeking shareholder approval for several resolutions, including the potential issuance of securities in non-public offerings to raise capital.